Lonza Group AG is a global leader in contract development and manufacturing (CDMO) for the pharmaceutical, biotech, and nutrition industries. It is the world's pre-eminent pure-play CDMO, commanding an estimated 18% share of the global outsourced biologics market.

• Unrivaled Capacity: Only CDMO with immediately available large-scale mammalian biologic capacity in the United States, anchored by the Vacaville facility (332,000 liters).
• Technical Expertise: Proven track record in complex manufacturing, including exclusive production for Moderna’s Covid-19 vaccine and Vertex’s Casgevy gene therapy.
• Switching Costs: Deep integration into pharma partner supply chains with long-term commercial contracts (five already signed for Vacaville).
• Pure-Play Focus: Structural pivot to biologics and advanced modalities enhances operational excellence and resource allocation.

• Vacaville Acquisition: Purchased the large-scale manufacturing site in California from Roche/Genentech, adding significant capacity and five long-term contracts.
• BIOSECURE Act Tailwinds: Positioned as the primary structural beneficiary of Western pharma demand redirecting away from Chinese CDMOs due to US legislative pressure.
• ADC Collaboration: Extended antibody-drug conjugate (ADC) supply collaboration with a major pharmaceutical partner.
• Strategic Divestiture: Sale of the Capsules & Health Ingredients unit (closing H2 2026) to Lone Star Funds for CHF 2.3 billion.

• Operational Challenges: Cell & Gene (Specialized Modalities) experienced a 3% organic sales decline in 2025.
• Execution Risk: High complexity in tech transfers and infrastructure investment at the newly acquired Vacaville site.
• Biotech Funding: Sensitivity to the broader biotech funding environment, which can impact early-phase clinical production demand.
• Currency Exposure: Significant exposure to currency fluctuations, with a projected 2% headwind in 2026.